China's FusoGen Pharmaceuticals has developed a new HIV fusion inhibitor that is currently in human clinical trials, Agence France-Presse reports. FusoGen CEO Zhou Genfa told the news agency that the drug, which has been registered as a new medicine with China's State Food and Drug Administration, is modeled on Fuzeon, the U.S. drug developed and marketing by Roche and Trimeris, but that the Chinese medication uses a different molecular modeling. The company hopes to have the drug available in China by the end of 2006 and says it will be priced considerably lower than Fuzeon, which costs U.S. HIV patients about $20,000 per year.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved















